EE245 Continuous Avoidance Cost in Biosimilar: A Budget Impact Analysis on the Basis of Clinical Trial Model and RWD in Brazil / LATAM / LMIC
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.1844
https://www.valueinhealthjournal.com/article/S1098-3015(25)01973-4/fulltext
Title :
EE245 Continuous Avoidance Cost in Biosimilar: A Budget Impact Analysis on the Basis of Clinical Trial Model and RWD in Brazil / LATAM / LMIC
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)01973-4&doi=10.1016/j.jval.2025.04.1844
First page :
Section Title :
Open access? :
No
Section Order :
10040